Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH

NCT00633880 is registered in ClinicalTrials.gov with Chelsea Therapeutics as lead sponsor.

NCT NCT00633880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00633880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH
Lead sponsor
Chelsea Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2008
Completion date
September 30, 2009
Enrollment
181 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

dopamine beta hydroxylase deficiency, non-diabetic neuropathy, primary autonomic failure, symptomatic neurogenic orthostatic hypotension (noh)